drugset / Trial / NCT00092365

A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)

NCT00092365

Phase 3 Completed 413 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.

Timeline

Start
2003-04-01
Primary completion
2003-11-01
Completion
2003-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg
Subject rofecoxib Small molecule 12.5 mg

Indications